IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0242982.html
   My bibliography  Save this article

Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis

Author

Listed:
  • Guocan Yu
  • Yanqin Shen
  • Xudong Xu
  • Fangming Zhong

Abstract

Objective: To assess the efficacy and toxicity of anlotinib for the treatment of refractory advanced non-small-cell lung cancer (NSCLC). Methods: We systematically searched databases for randomized controlled trials on anlotinib treatment for patients with advanced NSCLC published until November 6, 2020. Articles were assessed and data were extracted independently by two investigators. Further, we analyzed hazard ratios (HRs) for progression-free and overall survival (PFS and OS, respectively). In addition, we analyzed risk ratio (RR) for overall response and disease control rates (ORR and DCR, respectively) and the odds ratio (OR) for the main adverse events (AEs) using RevMan 5.3 software. Results: This analysis included 594 patients from three clinical studies. The pooled HRs for PFS and OS were 0.27 (95% confidence interval (CI): 0.22–0.33, P

Suggested Citation

  • Guocan Yu & Yanqin Shen & Xudong Xu & Fangming Zhong, 2020. "Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis," PLOS ONE, Public Library of Science, vol. 15(11), pages 1-12, November.
    • Handle: RePEc:plo:pone00:0242982
    DOI: 10.1371/journal.pone.0242982
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242982
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0242982&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0242982?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Guocan Yu & Wenfeng Yu & Xudong Xu & Bo Ye & Liwei Yao, 2021. "Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis," PLOS ONE, Public Library of Science, vol. 16(6), pages 1-7, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0242982. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.